Contineum Therapeutics, Inc.
CTNM
28 insider filings · Latest: Jul 8, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Jul 10 9:20 PM | Daniel S. LorrainChief Scientific Officer | Sale | 25 | $16.00 | $400 | 135,202(D) | View → |
| Jul 8, 2026 | Jul 10 9:20 PM | Daniel S. LorrainChief Scientific Officer | Sale | 1,015 | $16.00 | $16.2K | 135,202(D) | View → |
| Jul 8, 2026 | Jul 8 10:49 PM | Carmine N. StengoneDirector, CEO and President | Sale | 2,500 | $16.00 | $40.0K | 17,217(D) | View → |
| Jul 8, 2026 | Jul 8 8:39 PM | CARMINE STENGONE | Proposed Sale | 2,500 | $14.56 | $36.4K | — | View → |
| Jul 1, 2026 | Jul 2 9:47 PM | Daniel S. LorrainChief Scientific Officer | Sale | 8,353 | $15.84 | $132.3K | 135,202(D) | View → |
| Jun 30, 2026 | Jul 2 9:47 PM | Daniel S. LorrainChief Scientific Officer | Sale | 28,826 | $16.04 | $462.3K | 139,372(D) | View → |
| Jun 30, 2026 | Jul 1 11:04 PM | Tim WatkinsCMO & Head of Development | Sale | 10,833 | $16.02 | $173.6K | 8,961(D) | View → |
| Jun 30, 2026 | Jul 1 11:04 PM | Carmine N. StengoneDirector, CEO and President | Sale | 10,000 | $16.01 | $160.1K | 17,217(D) | View → |
| Jul 1, 2026 | Jul 1 8:34 PM | Daniel Lorrain | Proposed Sale | 9,520 | $16.39 | $156.0K | — | View → |
| Jun 30, 2026 | Jun 30 8:38 PM | Daniel Lorrain | Proposed Sale | 28,826 | $15.00 | $432.4K | — | View → |
| Jun 30, 2026 | Jun 30 8:38 PM | CARMINE STENGONE | Proposed Sale | 10,000 | $15.00 | $150.0K | — | View → |
| Jun 30, 2026 | Jun 30 8:37 PM | TIMOTHY WATKINS | Proposed Sale | 10,833 | $15.00 | $162.5K | — | View → |
| Jun 1, 2026 | Jun 1 10:08 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,170 | $13.16 | $54.9K | 139,372(D) | View → |
| Jun 1, 2026 | Jun 1 8:19 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $13.49 | $56.3K | — | View → |
| May 1, 2026 | May 1 9:42 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,170 | $13.12 | $54.7K | 143,542(D) | View → |
| May 1, 2026 | May 1 8:47 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $12.82 | $53.5K | — | View → |
| Apr 6, 2026 | Apr 6 9:43 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,170 | $13.43 | $56.0K | 147,712(D) | View → |
| Apr 6, 2026 | Apr 6 8:33 PM | DANIEL LORRAIN | Proposed Sale | 914 | $13.44 | $12.3K | — | View → |
| Mar 2, 2026 | Mar 2 11:30 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,170 | $15.01 | $62.6K | 151,882(D) | View → |
| Mar 2, 2026 | Mar 2 11:28 PM | Tim WatkinsCMO & Head of Development | Sale | 3,611 | $15.02 | $54.2K | 0(D) | View → |
Page 1 of 2
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Jul 10 9:20 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 25 | $1.01 | 33,257(D) | View → |
| Jul 8, 2026 | Jul 10 9:20 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 1,015 | $1.01 | 33,282(D) | View → |
| Jul 8, 2026 | Jul 8 10:49 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 2,500 | $1.01 | 279,430(D) | View → |
| Jul 1, 2026 | Jul 2 9:47 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 4,183 | $1.01 | 34,297(D) | View → |
| Jun 30, 2026 | Jul 2 9:47 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 28,826 | $1.01 | 38,480(D) | View → |
| Jun 30, 2026 | Jul 1 11:04 PM | Tim WatkinsCMO & Head of Development | Option Exercise | 10,833 | $4.50 | 238,334(D) | View → |
| Jun 30, 2026 | Jul 1 11:04 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 10,000 | $1.26 | 118,417(D) | View → |
| Jun 26, 2026 | Jun 26 9:46 PM | Gines Diego MirallesDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:45 PM | Lori Lyons-WilliamsDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:44 PM | Olivia C WareDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:44 PM | Evert B. SchimmelpenninkDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:43 PM | Troy A. IgnelziDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:43 PM | Todd R. BradyDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:42 PM | Sarah BoyceDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Mar 2, 2026 | Mar 2 11:28 PM | Tim WatkinsCMO & Head of Development | Option Exercise | 3,611 | $4.50 | 249,167(D) | View → |
| Feb 25, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 2,700 | $1.26 | 120,917(D) | View → |
| Feb 24, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 4,400 | $1.26 | 123,617(D) | View → |
| Feb 25, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 3,824 | $1.01 | 67,306(D) | View → |
| Feb 24, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 4,300 | $1.01 | 71,130(D) | View → |
| Feb 19, 2026 | Feb 20 9:05 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 100 | $1.01 | 75,430(D) | View → |
Page 1 of 2
Next →